Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...

Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...

Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

Almirall SA ($GB:0O9B) announced an update on their ongoing clinical study. Study Overview: Almirall S.A. is running a phase 2 trial called “A ...

Individuals with a rare form of epilepsy treated with fenfluramine experienced significantly greater seizure reduction as ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.

Response and remission rates failed to beat placebo in a new Harvard meta-analysis, throwing the inflammation hypothesis into ...

Tramadol is widely prescribed for chronic pain, but a new review suggests the relief is modest and the risks may be greater than many realize.

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...